Source: ForexTV

Zosano Pharma: Zosano Pharma Receives Preliminary FDA Communication on Qtrypta NDA

FREMONT, Calif., Sept. 30, 2020 (GLOBE NEWSWIRE) - Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company today announced that it has received a discipline review letter (DRL) from the U.S. Food and Drug Administration (FDA) in connection with the Qtrypta (zolmitriptan transdermal microneedle system) 505(b)(2) New Drug Application (NDA). A DRL is used by the ...The post Zosano Pharma Receives Preliminary FDA Communication on Qtrypta NDA appeared first on ForexTV.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Steven Lo's photo - President & CEO of Zosano Pharma

President & CEO

Steven Lo

CEO Approval Rating

83/100

Zosano Pharma is a clinical-stage biopharmaceutical company that researches, develops and commercializes novel therapeutics to treat migraines. Read more